Vaxin Inc., a clinical stage vaccine and immunotherapeutics company, has been granted Notices of Allowance from the USPTO for two new patents protecting elements of its hepatitis B and influenza vaccine candidates. The patents cover an aqueous formulation for Vaxin's HepTcell hepatitis B immunotherapy product and the intranasal administration of its NasoVax influenza vaccine to induce immune responses. With these additions, Vaxin now has 37 patents in 13 countries protecting its products. The company is on track to begin three phase 1 clinical trials within the next 9 months.